© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
All News
Esophageal Cancer Update
February 06, 2023
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.
FDA Updates for the Week of Jan 30, 2023
February 04, 2023
The FDA has approved two breast cancer therapies this week: Trodelvy to treat patients with HR+/HER2- breast cancer and Orserdu to treat patients with ER+, HER2-, ESR1-mutated disease. The agency also approved a novel therapy for CKD-related anemia and Tezspire in pre-filled pen.
Shedding Light on Healthcare’s Dark Arts
February 03, 2023
François de Brantes, a member of the Managed Healthcare Executive ® editorial advisory board and senior partner at High Value Care Incentives Advisory Group LLC, describes what he believes has caused a major inflection point in the management, delivery and payment of U.S. healthcare
Wrist-Wearable Devices Can Identify Adverse Changes in Trauma Survivors
February 02, 2023
Certain biomarkers identified by these devices can be used to identify survivors of trauma who need further evaluation.
Rick Bates of RxSense Talks Collab With Mark Cuban's Cost Plus Drugs, Direct-To-Consumer Business and More
February 02, 2023
In this month’s episode of Tuning In to the C-Suite, Managing Editor Peter Wehrwein talks with Rick Bates, MBA, president and CEO of RxSense. In his conversation with Wehrwein, Bates described RxSense as a “technology platform company that has expertise in the direct-to-consumer business.” He emphasized that RxSense is not a pharmacy benefit manager (PBM) — but, rather, a company that supplies PBMs with technology, including some of the up-and-coming PBMs, such as EmsanaRx and Vivid Clear Rx. Bates and Wehrwein also discussed the Mark Cuban Cost Plus Drug and RxSense launching a standalone business intelligence product called Rx IQ.
Though Funding for Telehealth Is Declining, It Doesn't Mean All Virtual Care Isn't Investable
February 01, 2023
It's been reported more often now that funding for telehealth has decreased and it will only continue to do so into the year. Funding has likely decreased because the video/virtual care medium has become a commodity, according to Summus CEO and Founder, Julian Flannery.
For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition
February 01, 2023
A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.
After a Slow 2022, Healthcare M&A Poised To Pick Up in 2023, Says Bain
February 01, 2023
Larger payers have plenty of cash on hand to do deals but will look for “adjacencies” rather than merger and acquisition with other payers because of the regulatory environment, say Bain experts.
Insurers Prepare to Fight RADV Rule
January 31, 2023
The Risk Adjustment Data Validation (RADV) rule was finalized today. The new rule for governing how CMS audits Medicare Advantage plans for overpayment due to inflated risk adjustment could cost insurers billions of dollars.
Virtual Care is Evolving into 2023
January 30, 2023
Virtual care has been a favored service among many healthcare consumers as its users have shared they want more out of it, according to a 2022 Virtual Care Survey Report by Summus.